Multiple Myeloma (MM)
Multiple Myeloma (MM) is a hematologic neoplastic disease in which uncontrolled proliferation of clonal plasma cells’ leads to end-organ damage. MM is the second most common hematologic malignancy and accounts for 10% of all blood cancer cases. The median age for diagnosis is 65 years, with fewer than 3% of patients presenting when they are younger than 40 years. MM disproportionally affects black males.
It is estimated that 34,470 new cases of MM and 12,640 deaths related to the disease will occur in the US in 2022. The prognosis of patients is poor and the 5-year relative survival is 60%. MM and its treatment are frequently characterized by recurrent relapses and shorter remissions.
Cellectis’ UCARTCS1 is an allogeneic CAR T product that is being evaluated in the MELANI-01 study in adult patients with relapsed or refractory Multiple Myeloma (r/r MM). This product candidate has the potential to become an off-the-shelf available therapy for adult patients with r/r MM that uniquely targets CS1.